Table 1.
Prevalence and profile of autoantibodies in the study group.
| Autoantibody | n/N (%) |
|---|---|
| ANA | 10/51 (19.6%) |
| Titer: | |
| 1:80 | 6/10 (60%) |
| 1:160 | 2/10 (20%) |
| 1:320 | 1/10 (10%) |
| 1:640 | 1/10 (10%) |
| ENA | 0/10 (0%) |
| RF | 4/49 (8.2%) |
| ANCA | 5/50 (10%) |
| Titer: | |
| 1:80 | 1/5 (20%) |
| 1:160 | 3/5 (60%) |
| 1:320 | 1/5 (20%) |
| aCL IgG | 8/51 (15.7%) |
| aCL IgM | 4/51 (7.8%) |
| aCL IgG and/or IgM | 11/51 (21.6%) |
| Anti-beta2GP I IgG | 1/11 (9.1%) |
| Anti-beta2GP I IgM | 1/11 (9.1%) |
| Number of positive autoantibodies: | |
| 0 | 32/51 (62.7%) |
| 1 | 11/51 (21.6%) |
| ≥2 | 8/51 (15.7%) |
| Any positive autoantibody | 19 (37.3%) |
ANA, antinuclear antibodies; ENA, extractable nuclear antigens; ANCA, anti-neutrophil cytoplasmic antibodies; aCL, anti-cardiolipin antibodies; anti-β2-GPI, anti-beta2-glycoprotein I antibodies; RF, rheumatoid factor.